Osaka, Japan, February 28, 2025 – Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President: Toichi Takino, “ONO') announced that it has reorganized the operations of its local subsidiaries in the United States and the United Kingdom in order to accelerate the expansion of its global presence.

日本大阪，2025年2月28日——小野药品工业株式会社（大阪，日本；总裁：泷野藤一，“ONO”）宣布，为加速其全球业务扩展，已对其在美国和英国的当地子公司业务进行了重组。

In line with the reorganization, key functions of ONO PHARMA USA, INC. (Cambridge, Massachusetts, “OPUS”), including US R&D and commercial and medical affairs, and R&D in Europe, are being integrated into Deciphera Pharmaceuticals, LLC. (Deciphera) in July 2025. Deciphera has robust and well-developed R&D capabilities and commercial presence in the US and Europe.

根据重组计划，小野制药美国公司（ONO PHARMA USA, INC.，位于马萨诸塞州剑桥，简称“OPUS”）的关键职能，包括美国的研发、商业和医学事务，以及欧洲的研发，将于2025年7月整合至Deciphera Pharmaceuticals, LLC（简称Deciphera）。Deciphera在美国和欧洲拥有强大且成熟的研发能力及商业布局。

This integration will advance efforts to strengthen Deciphera as a business hub for the Ono Group*, responsible for R&D and sales and marketing operations in the US and Europe in other therapeutic areas in addition to existing oncology efforts. Related to these changes, the R&D functions of ONO PHARMA UK LTD.

此次整合将推动加强Deciphera作为小野集团*的业务枢纽，除了现有的肿瘤领域工作外，还负责美国和欧洲在其他治疗领域的研发、销售及营销运营。与此变动相关，ONO PHARMA UK LTD. 的研发职能。

(London, “OPUK”) will cease operations in March 2025..

（伦敦，“OPUK”）将于2025年3月停止运营。

OPUS will remain as a center for research collaboration and licensing activities, and OPUK will continue to operate as a center for research collaboration activities.

OPUS将继续作为研究合作和许可活动的中心，而OPUK将继续作为研究合作活动的中心运作。

Ono will continue its efforts to become a global specialty pharma company that delivers innovative pharmaceuticals to patients around the world as quickly as possible.

小野将继续努力成为一家全球性的专业制药公司，尽快为世界各地的患者提供创新药物。

*The Ono Group refers to the umbrella organization that includes Ono Pharmaceutical Co., Ltd. and its subsidiary companies.

*Ono集团是指包括小野药品工业株式会社及其子公司的伞形组织。

About Ono Pharmaceutical Co., Ltd.

关于小野药品工业株式会社

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company dedicated to creating innovative medicines in specific disease areas. Ono Pharma focuses on oncology, immunology, neurology, and specialty research, prioritizing areas with high medical needs for the discovery and development of innovative new treatments.

总部位于日本大阪的ONO制药公司是一家以研发为导向的制药企业，致力于在特定疾病领域开发创新药物。ONO制药专注于肿瘤学、免疫学、神经学和特色研究，优先选择医疗需求高的领域来发现和开发创新型治疗方法。

Founded in 1717 in Osaka, the company has facilities in Japan, the UK, the US, South Korea, and Taiwan. In June 2024, Ono Pharma acquired Deciphera Pharmaceuticals Inc., based in Massachusetts, USA, to strengthen its drug pipeline and support global expansion efforts..

成立于1717年的大阪，该公司在日本、英国、美国、韩国和台湾设有设施。2024年6月，小野制药收购了总部位于美国马萨诸塞州的Deciphera Pharmaceuticals Inc.，以加强其药物研发管线并支持全球扩展计划。

For further information visit:

欲了解更多信息，请访问：

https://www.ono-pharma.com/en

https://www.ono-pharma.com/cn